Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) and Senti Biosciences (NASDAQ:SNTI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.
This table compares Voyager Therapeutics and Senti Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Voyager Therapeutics and Senti Biosciences’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Voyager Therapeutics||$194.87 million||1.81||-$46.41 million||$2.27||3.54|
|Senti Biosciences||$4.29 million||5.48||-$58.21 million||($1.64)||-0.32|
This is a summary of current ratings and price targets for Voyager Therapeutics and Senti Biosciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Voyager Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 109.88%. Senti Biosciences has a consensus price target of $4.00, indicating a potential upside of 665.55%. Given Senti Biosciences’ higher possible upside, analysts clearly believe Senti Biosciences is more favorable than Voyager Therapeutics.
Volatility & Risk
Voyager Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500.
Institutional and Insider Ownership
58.8% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 27.4% of Senti Biosciences shares are owned by institutional investors. 4.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Senti Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Voyager Therapeutics beats Senti Biosciences on 9 of the 13 factors compared between the two stocks.
About Voyager Therapeutics
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
About Senti Biosciences
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.